Journal article
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: Outcomes in the Japanese subgroup of the VIEW 2 study
- Abstract:
-
Background/aims To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial. Methods In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after 3 monthly injections; or 0.5 mg ranibizumab every 4 weeks (Rq4). Main efficacy outcomes included vision maintenance and best-corrected visual...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 1.2MB)
-
- Publisher copy:
- 10.1136/bjophthalmol-2014-305076
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group Publisher's website
- Journal:
- British Journal of Ophthalmology Journal website
- Volume:
- 99
- Issue:
- 1
- Article number:
- 92
- Publication date:
- 2014-08-01
- DOI:
- EISSN:
-
1468-2079
- ISSN:
-
0007-1161
- Source identifiers:
-
481500
Item Description
- Language:
- English
- UUID:
-
uuid:459ff968-ae34-4c3e-a27f-d78ab7ea6b3d
- Local pid:
- pubs:481500
- Deposit date:
- 2014-09-10
Terms of use
- Copyright holder:
- Ogura et al
- Copyright date:
- 2014
- Notes:
- Copyright © 2014 Ogura et al. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
If you are the owner of this record, you can report an update to it here: Report update to this record